102134A novel enzymatic means to confirm correct and safe nasogastric tube placementClosedCollaborative R&DInnovate UKOur pilot study (n= 23, including 15 patients on antacid medications) found this new test was 100% accurate. The results, if validated further in this proposed, thorough clinical evaluation and scientific device development programme, mean that the new test would reduce feeding incidents due to misinterpretation of pH strip and X-ray results and cut the need for chest x-rays by about a third. Wider benefits to healthcare providers and patients include 1) significant cost savings (£1 per enzymatic test versus £120 per x-ray); 2) reduced risk of misdiagnosis of misplaced NG tubes; 3) biopsychosocial improvements for patients, 4) greater confidence and reliability in nursing care and 5) improved patient care and safety. Upon validation, there would be clear potential to apply related enzymatic marker detection more broadly to detect disease, health monitoring and infection.